Semax (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously. Most human nootropic studies use intranasal dosing in the range of

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake vigorously).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 3.33 mg/mL, 1 unit = 0.01 mL » 33.3 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in dry, dark conditions; minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C; stable for up to 30 days; avoid freeze-thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Protect from light; wrap vials in foil or store in an opaque container.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration.

Peptide Vials (Semax, 10 mg each):

• 8 weeks: ~4 vials. 12 weeks: ~6 vials. 16 weeks: ~8 vials.

Insulin Syringes (U-100):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (4 vials): 2 bottles. 12 weeks (6 vials): 2 bottles. 16 weeks (8 vials): 3 bottles.

Alcohol Swabs:

• Per week: 14 swabs.
• 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) at least 1 to 2 inches from previous sites to reduce

local irritation.

• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose, injection time, and site rotation to maintain consistency.
• Most human data are for 4 to 8 weeks of continuous use; longer protocols should incorporate rest

periods.

How This Works

Semax is a synthetic analog of the ACTH(4-10) fragment with a C-terminal Pro-Gly-Pro tripeptide extension that enhances metabolic stability. Clinical and preclinical literature suggest it modulates brain-derived neurotrophic factor (BDNF) expression, enhances cholinergic and dopaminergic neurotransmission, and exhibits neuroprotective properties in models of cerebrovascular and cognitive impairment. Human studies in Russia have employed Semax for cognitive support in conditions ranging from mild cognitive impairment to acute stroke recovery, typically using intranasal administration. Subcutaneous delivery offers an alternative route with potentially more sustained systemic absorption.

Benefits & Side Effects

Observations from preclinical and clinical literature.

• May support attention, memory consolidation, and learning in clinical populations with cognitive deficits.
• Studied in neurological conditions including stroke, traumatic brain injury, and optic neuropathy with

favorable safety profiles in month-long human trials.

• Generally well tolerated; intranasal administration may cause minor nasal irritation; subcutaneous

injection may produce mild injection-site reactions.

• No significant elevations in cortisol or other adverse endocrine effects reported in clinical studies.
• Effects are dose-dependent; titration helps identify the minimum effective dose for individual response.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain consistent sleep schedules and prioritize 7 to 9 hours of quality sleep per night.
• Engage in regular aerobic exercise and cognitive training to reinforce neuroplastic adaptations.
• Follow a balanced diet rich in omega-3 fatty acids, antioxidants, and micronutrients that support brain

health.

• Manage stress through mindfulness, meditation, or other relaxation techniques.
• Stay mentally active with challenging tasks, learning new skills, and social engagement.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Comparative study of Semax administration routes (intranasal vs. subcutaneous) in animal models (Neuroscience and Behavioral Physiology).
2. Clinical trial of Semax in ischemic stroke patients (Journal of Neurology and Psychiatry, Russia).
3. Vidal Drug Reference (Russia): Semax 0.1% intranasal drops, human dosing guidelines.
4. Overview of Russian peptide drugs including Semax (Pharmaceutics, MDPI).